EZH2 inhibitors harm homologous recombination repair in ovarian cancer cell lines by downregulating the expression of nonhomologous recombination repair-associated genes and thus inhibiting homologous recombination repair by treating them with EZH2 inhibitors. This evidence concerns the gene EZH2 and ovarian carcinoma.